AcuCort (ACUC) Stock Overview
Operates as a pharmaceutical company. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
ACUC Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
AcuCort AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.76 |
| 52 Week High | SEK 1.26 |
| 52 Week Low | SEK 0.55 |
| Beta | 1.34 |
| 1 Month Change | -14.30% |
| 3 Month Change | 9.42% |
| 1 Year Change | -9.90% |
| 3 Year Change | -64.88% |
| 5 Year Change | -79.92% |
| Change since IPO | -84.27% |
Recent News & Updates
Recent updates
Shareholder Returns
| ACUC | SE Pharmaceuticals | SE Market | |
|---|---|---|---|
| 7D | 2.0% | -5.3% | 0.2% |
| 1Y | -9.9% | -1.2% | 5.2% |
Return vs Industry: ACUC matched the Swedish Pharmaceuticals industry which returned -9% over the past year.
Return vs Market: ACUC underperformed the Swedish Market which returned -1.7% over the past year.
Price Volatility
| ACUC volatility | |
|---|---|
| ACUC Average Weekly Movement | 9.1% |
| Pharmaceuticals Industry Average Movement | 9.4% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in SE Market | 11.6% |
| 10% least volatile stocks in SE Market | 3.0% |
Stable Share Price: ACUC has not had significant price volatility in the past 3 months compared to the Swedish market.
Volatility Over Time: ACUC's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 4 | Jonas Jonmark | www.acucort.com |
AcuCort AB (publ) develops and commercializes glucocorticoid dexamethasone films for the treatment of acute allergic conditions. It offers Zeqmelit, a medicine used for the treatment of severe and acute allergic reactions, croup in children, and chemotherapy-induced nausea and vomiting, as well as for the treatment of COVID-19 patients who need supplemental oxygen treatment. AcuCort AB (publ) was incorporated in 2006 and is based in Lund, Sweden.
AcuCort AB (publ) Fundamentals Summary
| ACUC fundamental statistics | |
|---|---|
| Market cap | SEK 170.71m |
| Earnings (TTM) | -SEK 20.31m |
| Revenue (TTM) | SEK 7.93m |
Is ACUC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ACUC income statement (TTM) | |
|---|---|
| Revenue | SEK 7.93m |
| Cost of Revenue | SEK 17.35m |
| Gross Profit | -SEK 9.42m |
| Other Expenses | SEK 10.88m |
| Earnings | -SEK 20.31m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.09 |
| Gross Margin | -118.87% |
| Net Profit Margin | -256.18% |
| Debt/Equity Ratio | 0% |
How did ACUC perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/06/29 10:42 |
| End of Day Share Price | 2025/06/27 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
AcuCort AB (publ) is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.